How AI is transforming pharmaceutical value creation – and why regulatory certainty is a prerequisite for its success.
Artificial intelligence (AI) can help the pharmaceutical industry in many ways: making processes more efficient, driving innovation, improving the quality of medicinal products. Whether in drug development, clinical trials, production or quality assurance – AI can analyse large volumes of data, recognise patterns and support employees with complex tasks. At the same time, its use places the industry in a particular position: in a strictly regulated environment, efficiency and innovation must always remain in harmony with patient safety, data integrity and compliance.
Whether AI succeeds in the pharmaceutical industry does not depend on its technical performance alone. Equally important is that systems run reliably, transparently and safely within a clear regulatory framework.
AI along the value chain
The potential of AI extends across almost every area of pharmaceutical value creation – above all in data-intensive and repetitive tasks, where it can achieve a great deal.
Research and drug development
In research, AI can analyse large volumes of biological, chemical and molecular data, identify promising drug candidates and support the selection of suitable substances. This makes research processes more targeted and surfaces development risks earlier.
There are also opportunities in the planning and conduct of clinical trials: for example in identifying suitable trial participants, evaluating study data or simplifying administrative tasks. The prerequisite remains that data protection, scientific validity and the applicable requirements for clinical trials are preserved.
Production and process optimisation
In manufacturing, AI can help monitor production processes more closely and detect deviations early. When process and sensor data are analysed, quality problems can often be identified before they affect the end product.
Another field of application is predictive maintenance: AI-supported systems use operating data to detect possible equipment failures before they occur, reducing unplanned downtime.
Visual quality control also benefits – for example through image processing systems that detect defects in tablets or packaging. Combined with process analytical technology (PAT), AI applications can also support real-time monitoring and optimisation of manufacturing processes.
Quality assurance and documentation
The use of AI in quality assurance is particularly exciting. Systems can evaluate large volumes of manufacturing and quality data, detect recurring deviations and support root-cause analysis. There is also considerable automation potential in CAPA measures, standard operating procedures (SOPs) and regulatory documents.
In addition, AI applications can relieve employees when searching for information, creating documentation drafts and identifying inconsistencies.
But this does not mean that expert review or responsibility become dispensable. AI results must be appropriately verified depending on the use case. Especially for quality-relevant decisions, automation must never lead to unverified results being adopted uncritically.
Regulation and compliance as the foundation
As great as the potential for innovation is, so too are the demands for safe and compliant use. Pharmaceutical companies bear a special responsibility here, because erroneous decisions have a direct impact on medicinal product quality – and therefore on patient safety.
Regulation and compliance therefore do not belong at the end of an AI project, but from the very beginning in planning, development, implementation and monitoring.
GMP requirements and validation
For AI applications in GMP-relevant processes, the first step is to clarify what influence the system has on product quality, patient safety and data integrity. This determines which controls, evidence and validation measures are required.
Companies must be able to demonstrate in a comprehensible way that a system is suitable for its intended purpose and functions reliably within defined limits. This includes an appropriate risk assessment, documented requirements, suitable tests and the control of relevant changes.
This is particularly demanding for AI systems, because results depend on the data used, the model parameters and the specific application situation. A one-off test whose result is assumed to hold permanently is therefore not sufficient. Depending on the technology and risk profile, changes in system behaviour, the data basis or the models must also be taken into account.
How deep the review needs to be depends on the intended use and the risk. Not every AI application requires the same depth of review – what matters is that the scope and intensity of controls are appropriately justified and documented.
Data integrity and traceability
The quality of AI results stands or falls with the quality of the data. Incomplete, erroneous or biased data leads to false conclusions. In the pharmaceutical industry it must therefore be ensured that data is processed completely, consistently, correctly and traceably.
At least as important is the documentation of processing steps and decisions. Depending on the use case, companies must be able to reconstruct which data and system versions were used, which results were generated and how these flowed into a decision.
This traceability is not a purely technical requirement. It is the foundation for internal audits, inspections and the investigation of quality incidents.
Special caution is required with generative AI: such systems occasionally produce plausible-sounding but factually incorrect information. Results must therefore not be adopted unchecked into quality-relevant documents, regulatory submissions or other controlled processes.
Risk management and human responsibility
Another central building block is risk-based control: before implementation, a systematic assessment should be made of which errors can occur, what consequences they would have and which countermeasures are necessary.
This includes defined limits of use, authorisation concepts, technical protective measures, monitoring mechanisms and clear escalation paths for unexpected results.
Equally important: assigning responsibilities unambiguously. Employees must know which tasks an AI system may take on, which results must be reviewed and who approves decisions. The company’s responsibility for regulatory requirements can be replaced neither by the use of an AI solution nor by an external technology provider.
What this means in practice – and what a tool like aiuno can do
The good news: not every company has to reinvent this rulebook from scratch. Tools that were developed for regulated environments from the outset anticipate a large part of these requirements.
One example is aiuno. The AI tool was built for use under strict compliance requirements and aligns its own way of working with the German Federal Lawyers’ Act (BRAO) – a regulatory framework that imposes similarly high standards of confidentiality, diligence and professional liability as those known from the pharmaceutical industry. What suffices for lawyers is therefore also a reliable benchmark for pharmaceutical processes.
Specifically, aiuno brings three properties that make the difference in a pharmaceutical context:
- Compliance at the highest level: The system operates within a clearly defined regulatory framework – not as a retrospective additional layer, but as a fundamental principle of its architecture.
- Seamless audit trail: Every processing step and every result is documented in a traceable way. This directly covers one of the central demands of data integrity – the reconstructability of decisions.
- High answer quality with human in the loop: The system is designed to exclude hallucinations as far as possible. However, the final assessment and approval remain with the human – the concept deliberately sees AI as support for the professional, not as their replacement.
aiuno can be used wherever documents, documentation and planning are concerned – precisely those areas where pharmaceutical companies have the greatest coordination and review effort: SOPs, CAPA documentation, deviation reports, regulatory documents, internal planning. What is not replaced is research in the narrower sense – drug development or laboratory analyses remain special applications that require their own tools.
For a company that wants to introduce AI, this means: the path to a validated, compliant deployment is shorter if the tool already brings the fundamental regulatory requirements with it. What remains is the company-specific validation for the concrete use case – not the fundamental question of whether the system can satisfy the regulatory requirements at all.
Compliance must accompany the entire life cycle
Compliant AI use requires a structured approach that goes beyond implementation. Already when selecting a use case, regulatory relevance, data availability, risks and expected benefits should be considered.
Subsequently, the requirements for the system, the necessary controls and the responsibilities must be defined. Before productive use, suitability for the intended purpose must be demonstrated. After implementation, performance, reliability and safety must be kept in view during ongoing operations – not only in professional terms, but also economically and strategically. Because with every integration, AI becomes more deeply interwoven with a company’s processes – and quickly indispensable.
Economic dependencies and architecture – an underestimated governance topic
What is often not considered during implementation: whoever integrates AI into core processes enters into dependencies that are difficult to reverse later. Price changes for models can then become considerable cost drivers. And this is realistic to expect – many models are subsidised today, and it is questionable how long current prices will hold. Anyone who aligns their processes with a single model at current price conditions bears a cost risk they do not control themselves.
A political factor comes on top: AI models are not immune to regulatory or geopolitical influences. Models can be switched off, restricted or reassessed in new jurisdictions. An architecture that does not provide for a model change can then suddenly face a real problem.
These risks result in a clear consequence for the architecture: it should be model-agnostic, so that models can be replaced as needed without processes and integrations having to be rebuilt. And it should work token-efficiently, because the most effective lever against cost increases is not negotiating prices, but the economical use of the quantity consumed.
A third aspect is gaining weight: data centre capacities are limited, and the energy consumption of AI is increasingly becoming a cost and sustainability issue. A modern AI architecture therefore deploys models selectively – the right model for the right task, not the most powerful available model for every small sub-task. Those who steer intelligently here save energy and costs at the same time.
These points are often treated as purely technical issues. In fact, they are governance issues: they concern cost control, dependency management and the company’s long-term ability to steer. They therefore belong in the same assessment as the regulatory questions – ideally from the very beginning, as long as the architecture decisions are still open. This is exactly where aiuno comes in: the platform is designed to be model-agnostic and token-efficient, so that model changes and price changes remain manageable and the use of individual models is oriented towards actual needs rather than maximum consumption.
Governance concept at a glance
An effective governance concept includes:
- Clear responsibilities: Who is responsible for the selection, approval, operation and monitoring of the AI application?
- Risk-based assessment: Classification of the use case according to its possible effects on product quality, patient safety and compliance.
- Documentation and validation: Evidence of requirements, tests, approvals, changes and system suitability.
- Data and access protection: Appropriate access rights, data quality and protective measures.
- Continuous monitoring: Regular assessment of results, error patterns and changes in system behaviour.
- Economic robustness: Model-agnostic, token-efficient architecture to keep cost risks from price changes, model shutdowns or limited computing capacities under control.
- Employee training: How the deployed AI technologies work, their limits and their risks.
Regulatory requirements must always be seen in the context of the respective application. In addition to GMP requirements, requirements for clinical trials, data protection, electronic records and signatures as well as the European AI legal framework may also be relevant depending on the area of use. The EU AI Act is as little applicable across the board as the GMP requirements themselves – what is decisive is the intended purpose, risk category and specific use of the system.
The human remains decisive
Despite increasing automation, the professional competence of employees remains the most important success factor. AI can accelerate analyses, show correlations and prepare decisions. But it does not automatically have the process understanding or the ability to reliably assess all regulatory consequences of its results.
This is exactly where the human-in-the-loop concept that aiuno envisages comes in: the AI delivers drafts, analyses and suggestions – the professional assessment and approval remain with the human. Employees must be trained accordingly in order to evaluate AI results critically and recognise their limits.
Departments, IT, quality assurance, regulatory affairs, data protection and compliance should sit at the same table early on – this is the only way to bring together technical possibilities and the requirements of operations and the regulatory environment. This prevents AI projects from being created solely from an efficiency perspective and controls from having to be laboriously retrofitted later.
Conclusion: innovation and regulatory certainty belong together
Artificial intelligence offers the pharmaceutical industry considerable opportunities: it can accelerate drug development, optimise production processes, support quality assurance and simplify the handling of complex data. But its benefit does not arise from automation or powerful models alone.
Decisive is the ability to integrate AI in a controlled and responsible way into existing processes. Especially in a highly regulated industry, data integrity, validation, risk management, documentation and clear responsibilities are part of it from the very beginning. Tools like aiuno, which anchor compliance, audit trail and ultimate human responsibility in their architecture from the start, show that this standard can be implemented practically today – wherever documents, documentation and planning are the focus.
Regulation and compliance are not brakes on innovation. They create the conditions for AI to be used in a trustworthy, traceable and sustainable way. A consistently risk-based approach allows pharmaceutical companies to exploit the potential of new technologies – without losing sight of medicinal product quality and patient safety.
The decisive success factor is therefore not the fastest possible introduction of AI, but its professionally sound, regulatorily secured and continuously monitored use.